Preparation Of Poly(Lactic Acid Glycolic Acid) Based Nanoparticles And Its Application In The Treatment Of Severe Bronchial Asthma

In order to solve the problem of low water solubility (<30 ng/mL) and low bioavailability of psoralen dihydroflavone methyl ether (PDME), nanotechnology is used to construct an oral nanosphere material, which is based on poly(lactic acid glycolic acid) (PLGA) and encapsulates PDME. The therapeutic performance of the material is evaluated from the characterization of the material, the number of inflammatory cells in the lung and the way of lung CT scanning. The results show that the dispersion of the nano material is uniform, the particle size is uniform, and the nanomaterials are homogeneous spheres. In vitro sustained-release test show that the nanomaterials can release drug slowly and have no toxicity. In the detection of CT and bronchoalveolar lavage fluid in patients with severe bronchial asthma, it is found that PLGA-PDME nanomaterials can achieve good diffusion in the lungs of patients with severe bronchial asthma, and can effectively reduce the number of inflammatory cells in the lung, reduce the level of related inflammatory factors, significantly reduce the infiltration of bronchial and perivascular, and reduce the production of goblet cells, which can effectively alleviate the patients' lung inflammation airway hyperresponsiveness. Through the above experiments, it is proved that the nano drug carrier PLGA-PDME has drug delivery, can effectively inhibit the growth of inflammatory cells, and can alleviate the further deterioration of severe asthma symptoms in patients, and provide a new idea for drug treatment of asthma diseases.